| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Tau mRNA. TauASO-12 (murine) (sodium) is an antisense oligonucleotide (ASO) that targets the messenger RNA (mRNA) encoding the tau protein. It binds to the tau mRNA through complementary base pairing, leading to its degradation by RNase H. This prevents translation of the tau protein, reducing its cellular levels.
|
|---|---|
| ln Vitro |
TauASO-12 (murine) reduces tau protein levels in neuronal cultures. In vitro, the ASO efficiently enters cells, binds to the tau mRNA, and triggers its degradation. This results in a concentration-dependent reduction in tau protein expression, which can be measured by Western blot or ELISA. A scrambled ASO sequence is used as a negative control.
|
| ln Vivo |
In vivo, TauASO-12 (murine) is a Tau-lowering antisense oligonucleotide that has been shown to prevent neuronal loss and reverse pathological tau deposition and seeding in mice with tauopathy. Administration of this ASO leads to reduced tau protein levels in the brain, which translates into improved neurological function and extended survival in mouse models.
|
| Enzyme Assay |
Not applicable. TauASO-12 is an ASO that binds to RNA rather than a protein. Its activity is assessed by measuring target RNA levels by qRT-PCR and target protein levels by Western blot in cells or tissues. In vitro target engagement assays are based on these molecular biology techniques rather than traditional receptor binding.
|
| Cell Assay |
Primary neuronal culture or cell line (e.g., N2a cells expressing tau) is seeded in 6-well plates. Cells are treated with TauASO-12 (murine) (sodium) at concentrations of 0.1-1000 nM using a transfection reagent or gymnotic (free uptake) delivery for 24-72 h. RNA is extracted for tau mRNA quantification by qRT-PCR. Cell lysates are analyzed for tau protein levels by Western blot.
|
| Animal Protocol |
Tau transgenic mouse model (e.g., P301S tau mice). Mice (6-8 weeks old) receive intracerebroventricular (ICV) infusion of TauASO-12 (murine) (sodium) (100-500 ug) via an osmotic minipump over 4 weeks. Alternatively, a single ICV bolus injection can be given. After treatment, brain tissues are collected for tau protein analysis by Western blot. Cognitive function is assessed by Morris water maze, and tau pathology is assessed by immunohistochemistry.
|
| ADME/Pharmacokinetics |
As an antisense oligonucleotide, TauASO-12 (murine) (sodium) is administered by intracerebroventricular (ICV) injection or infusion directly into the central nervous system. It has a half-life of several weeks in the brain, enabling sustained tau reduction after a single administration. The sodium salt enhances solubility and stability. The ASO does not cross the blood-brain barrier efficiently.
|
| Toxicity/Toxicokinetics |
Toxicology data for TauASO-12 (murine) are being evaluated in preclinical studies. ASO toxicities can include pro-inflammatory effects in the CNS, including microglial activation and neuronal toxicity at high doses. Off-target hybridization to non-target mRNAs is possible. The compound is intended for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
TauASO-12 (murine) (sodium) is a research-grade antisense oligonucleotide for tauopathies. It has not been approved for human therapeutic use. This ASO is a valuable tool for studying the role of tau in neurodegeneration and for validating tau as a therapeutic target. The sequence is specific to murine tau and should not be used in human cells. For research use only.
|
| Molecular Weight |
7619.00
|
|---|---|
| Related CAS # |
IONIS-MAPTRx;2857842-32-9
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1313 mL | 0.6563 mL | 1.3125 mL | |
| 5 mM | 0.0263 mL | 0.1313 mL | 0.2625 mL | |
| 10 mM | 0.0131 mL | 0.0656 mL | 0.1313 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
